Prognostic value of poorly differentiated clusters in invasive breast cancer

World Journal of Surgical Oncology

Yili Wang¹  Hongyan Wang¹  Jianjun He¹  Kai Wang¹  Wei Cao⁴  Fenli Liang³  Ying Sun² 

[1] Center for Cancer Research, Department of Pathology, the First Affiliated Hospital of Xi’an Jiaotong University, 710061 Xi’an, China;Department of Pathology, School of Medicine, Xi’an Jiaotong University, Xi’an, China;Department of Pathology, Xi’an Medical College, Xi’an, China;Department of Oncology, Shaanxi Provincial People’s Hospital, Xi’an, China

关键词: Prognosis;    Poorly differentiated cluster;    Breast cancer;   

Others  :  1147806
DOI  :  10.1186/1477-7819-12-310

 received in 2014-04-14, accepted in 2014-10-01,  发布年份 2014

【 摘 要 】

Background

Our study aimed to assess the prognostic value of poorly differentiated clusters (PDCs) in invasive breast cancer.

Methods

A total of 146 cases of operable invasive ductal carcinoma that was not otherwise specified (IDC-NOS), from 2002 to 2009, were pathologically reviewed. Cancer clusters with five or more cancer cells and lacking gland-like structures were counted from a field containing maximum clusters in H & E slides under a × 20 objective lens (0.950 mm² field of vision).

Results

Tumors with <5, 5 to 9, and ≥10 clusters were graded as G1, G2, and G3, respectively (n =41, 60, and 45 tumors, respectively). An interobserver test showed good reproducibility, with a Cohen’s kappa coefficient of 0.739. The PDC grade was significantly associated with N stage (P <0.001), lymphovascular invasion (P =0.007), tumor budding grade (P <0.001), relapse rate (P <0.001), and death rate (P <0.001). Survival analyses revealed that the PDC grade was a significant prognostic factor for disease-free survival (hazard ratio 3.811; P <0.001) and overall survival (hazard ratio 3.730; P =0.001), independent of T stage, N stage, or tumor budding grade.

Conclusions

The PDC grade is an independent prognostic factor of IDC-NOS. Considering the simplicity and availability of this method relative to conventional clinical pathology, PDCs may serve as a novel prognostic histological characteristic in IDC-NOS.

【 授权许可】

   
2014 Sun et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Freedman LS, Edwards DN, McConnell EM, Downham DY: Histological grade and other prognostic factors in relation to survival of patients with breast cancer. Br J Cancer 1979, 40(1):44-55.
• [2]Alderson MR, Hamlin I, Staunton MD: The relative significance of prognostic factors in breast carcinoma. Br J Cancer 1971, 25(4):646-656.
• [3]Gujam FJ, Going JJ, Edwards J, Mohammed ZM, McMillan DC: The role of lymphatic and blood vessel invasion in predicting survival and methods of detection in patients with primary operable breast cancer. Crit Rev Oncol Hematol 2014, 89(2):231-241.
• [4]Jung SY, Rosenzweig M, Sereika SM, Linkov F, Brufsky A, Weissfeld JL: Factors associated with mortality after breast cancer metastasis. Cancer Causes Control 2012, 23(1):103-112.
• [5]Chang J, Clark GM, Allred DC, Mohsin S, Chamness G, Elledge RM: Survival of patients with metastatic breast carcinoma: importance of prognostic markers of the primary tumor. Cancer 2003, 97(3):545-553.
• [6]Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN: Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol 2007, 608:1-22.
• [7]Knorr KL, Hilsenbeck SG, Wenger CR, Pounds G, Oldaker T, Vendely P, Pandian MR, Harrington D, Clark GM: Making the most of your prognostic factors: presenting a more accurate survival model for breast cancer patients. Breast Cancer Res Treat 1992, 22(3):251-262.
• [8]Hase K, Shatney C, Johnson D, Trollope M, Vierra M: Prognostic value of tumor ‘budding’ in patients with colorectal cancer. Dis Colon Rectum 1993, 36:627-635.
• [9]Kanazawa H, Mitomi H, Nishiyama Y, Kishimoto I, Fukui N, Nakamura T, Watanabe M: Tumour budding at invasive margins and outcome in colorectal cancer. Colorectal Dis 2008, 10:41-47.
• [10]Liang F, Cao W, Wang Y, Li L, Zhang G, Wang Z: The prognostic value of tumor budding in invasive breast cancer. Pathol Res Pract 2013, 209(5):269-275.
• [11]Karamitopoulou E, Zlobec I, Born D, Kondi-Pafiti A, Lykoudis P, Mellou A, Gennatas K, Gloor B, Lugli A: Tumour budding is a strong and independent prognostic factor in pancreatic cancer. Eur J Cancer 2013, 49(5):1032-1039.
• [12]Teramoto H, Koike M, Tanaka C, Yamada S, Nakayama G, Fujii T, Sugimoto H, Fujiwara M, Suzuki Y, Kodera Y: Tumor budding as a useful prognostic marker in T1-stage squamous cell carcinoma of the esophagus. J Surg Oncol 2013, 108(1):42-46.
• [13]Masuda R, Kijima H, Imamura N, Aruga N, Nakamura Y, Masuda D, Takeichi H, Kato N, Nakagawa T, Tanaka M, Inokuchi S, Iwazaki M: Tumor budding is a significant indicator of a poor prognosis in lung squamous cell carcinoma patients. Mol Med Rep 2012, 6(5):937-943.
• [14]Prall F: Tumour budding in colorectal carcinoma. Histopathology 2007, 50:151-162.
• [15]Jass JR, O’Brien MJ, Riddell RH, Snover DC, Association of directors of anatomic and surgical pathology: Recommendations for the reporting of surgically resected specimens of colorectal carcinoma. Hum Pathol 2007, 38:537-545.
• [16]Turner RR, Li C, Compton CC: Newer pathologic assessment techniques for colorectal carcinoma. Clin Cancer Res 2007, 13(22 Pt 2):6871s-6876s.
• [17]Ueno H, Mochizuki H, Hashiguchi Y, Ishiguro M, Kajiwara Y, Sato T, Shimazaki H, Hase K, Talbot IC: Histological grading of colorectal cancer: a simple and objective method. Ann Surg 2008, 247(5):811-888.
• [18]Ueno H, Kajiwara Y, Shimazaki H, Shinto E, Hashiguchi Y, Nakanishi K, Maekawa K, Katsurada Y, Nakamura T, Mochizuki H, Yamamoto J, Hase K: New criteria for histologic grading of colorectal cancer. Am J Surg Pathol 2012, 36(2):193-201.
• [19]Masood S: Raising the bar: a plea for standardization and quality improvement in the practice of breast pathology. Breast J 2006, 12:409-412.
• [20]Elston CW, Ellis IO: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991, 19(5):403-410.
• [21]Rampaul RS, Pinder SE, Elston CW, Ellis IO, Nottingham Breast Team: Prognostic and predictive factors in primary breast cancer and their role in patient management: The Nottingham Breast Team. Eur J Surg Oncol 2001, 27(3):229-238.
• [22]Imperato PJ, Waisman J, Wallen MD, Llewellyn CC, Pryor V: Improvements in breast cancer pathology practices among medicare patients undergoing unilateral extended simple mastectomy. Am J Med Qual 2003, 18(4):164-170.
• [23]Boros M, Marian C, Moldovan C, Stolnicu S: Morphological heterogeneity of the simultaneous ipsilateral invasive tumor foci in breast carcinoma: a retrospective study of 418 cases of carcinomas. Pathol Res Pract 2012, 208(10):604-609.
• [24]Jimenez RE, Wallis T, Visscher DW: Centrally necrotizing carcinomas of the breast: a distinct histologic subtype with aggressive clinical behavior. Am J Surg Pathol 2001, 25(3):331-337.
• [25]Jouanneau J, Tucker GC, Boyer B, Vallés AM, Thiery JP: Epithelial cell plasticity in neoplasia. Cancer Cells 1991, 3:525-529.
• [26]Shinto E, Mochizuki H, Ueno H, Matsubara O, Jass JR: A novel classification of tumour budding in colorectal cancer based on the presence of cytoplasmic pseudo-fragments around budding foci. Histopathology 2005, 47:25-31.
• [27]Ueno H, Hase K, Hashiguchi Y, Shimazaki H, Tanaka M, Miyake O, Masaki T, Shimada Y, Kinugasa Y, Mori Y, Kishimoto M, Kameoka S, Sato Y, Matsuda K, Nakadoi K, Shinto E, Nakamura T, Sugihara K: Site-specific tumor grading system in colorectal cancer: multicenter pathologic review of the value of quantifying poorly differentiated clusters. Am J Surg Pathol 2014, 38(2):197-204.
• [28]Barresi V, Bonetti LR, Ieni A, Branca G, Baron L, Tuccari G: Histologic grading based on counting poorly differentiated clusters in preoperative biopsy predicts nodal involvement and pTNM stage in colorectal cancer patients. Hum Pathol 2014, 45(2):268-275.
• [29]Giger OT, Comtesse SC, Lugli A, Zlobec I, Kurrer MO: Intra-tumoral budding in preoperative biopsy specimens predicts lymph node and distant metastasis in patients with colorectal cancer. Mod Pathol 2012, 25:1048-1053.
• [30]O’Brien , Pollett A, Gallinger S, Dick JE: A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007, 445:106-110.